Skip to main content

Genaissance Moves into Nutrigenomics with Sciona Licensing Deal

NEW YORK, Nov. 18 (GenomeWeb News) - Genaissance Pharmaceuticals today announced that it has licensed its HAP genotyping technology platform to consumer product biotech firm Sciona.

In exchange for the technology license, Genaissance obtained a 30 percent equity position in the privately traded UK-based company. Genaissance will receive royalties on any products Sciona develops using the HAP technology.

Kevin Rakin, president and CEO of Genaissance, called Sciona "a leader in the emerging market of integrating genetic variation into wellness products." The deal "continues the commercialization of our HAP technology in a variety of new markets," he added.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.